The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
HIF at a glance
Abstract
Hypoxia-inducible factor (HIF) is a sequence-specific DNA-binding protein that can promote or repress the transcription of a broad range of genes that are involved in maintaining biological homeostasis. HIF is mostly non-functional in oxygenated cells but becomes active under specific conditions, including low-oxygen (hypoxic) stress. HIF is a heterodimeric complex that is composed of an oxygen-destructible α-subunit and an oxygen-indestructible β-subunit. Three isoforms of the α-subunit and two isoforms of the β-subunit are thought to be involved in the in vivo response to hypoxia.HIF transcriptional activity requires inhibition of the post-transcriptional hydroxylation of the α-subunit, which targets HIF for proteasomal degradation and thereby causes its inactivation. In addition to hypoxic stress, several other conditions activate HIF transcriptional activity, including autocrine stimulation by growth factors, the loss of tumour-suppressor function and the gain of oncogene function. Overall, the genes targeted by HIF help cells to adapt to, and thereby survive in, a stressful microenvironment. Adaptation can be beneficial to human physiology in the context of foetal development and in many pathophysiological conditions, such as ischaemic disorders, but can be detrimental in the context of tumourigenesis. In this article and its accompanying poster, we briefly cover the major structural and functional characteristics of HIF and its involvement in conditions of normal physiology and in disease.The activities of three well-described HIFα isoforms (HIF1α, HIF2α and HIF3α) are regulated in a similar manner by post-translational prolyl hydroxylation of the oxygen-dependent degradation domain (ODDD) (Schofield and Ratcliffe, 2004). Prolyl hydroxylation targets the proteins for proteasomal degradation by promoting their interaction with von Hippel-Lindau (VHL), a component of an E3 multiprotein ubiquitin-ligase complex known as VHL/elongin B/elongin C (VBC). VBC covalently links a chain of ubiquitin (Ub) moities to HIFα and causes it to dock onto the multisubunit proteolytic proteasomal complex, which selectively degrades ubiquitin-conjugated proteins (Kaelin and Ratcliffe, 2008). Additional hydroxylation of an asparaginyl moiety at the end of the C-terminus of the HIF1α and HIF2α subunits abrogates HIF activation by inhibiting the binding of coactivators such as p300 and its paralogue CREB-binding protein (CBP), which also act as histone acetyltransferases. These hydroxylation events are catalysed, respectively, by prolyl hydroxylase domain proteins (PHDs), of which there are three major isoforms (Schofield and Ratcliffe, 2004), and factor inhibiting HIF (FIH) (Peet and Linke, 2006). These enzymes are dioxygenases and belong to the largest known family of non-haem oxidising enzymes (International Union of Biochemistry number EC 1.14.11.2). Their activity is dependent on substrates oxygen and 2-oxoglutarate (2-OG, a Krebs cycle intermediate) and on cofactor Fe2+.Under hypoxic conditions, PHDs and FIH are inactive because of the lack of sufficient oxygen. Both of these enzymes use oxygen and 2-OG as substrates in the hydroxylation reaction; however, they are very different with respect to the concentration of oxygen required for their activity. In vitro, PHD has a Michaelis constant (Km) for oxygen that is three times greater than that of FIH (Koivunen et al., 2004). Thus, as the oxygen concentration decreases, PHDs become inactive and the HIFα protein is consequently stabilised. Because HIFα has a nuclear localisation signal (NLS) in its C-terminal region, when stable it can rapidly bind to nuclear pore proteins and translocate into the nucleus (Kallio et al., 1998). However, HIFα may remain at least partially inactive until a further decrease in the oxygen concentration occurs, which inactivates FIH and fully activates HIF transcriptional activity.Once in the nucleus, the HIFα and HIFβ subunits interact with one another and bind to specific DNA sequences (Brahimi-Horn and Pouysségur, 2005). Dimerisation between the HIFα and HIFβ subunits occurs through the basic helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) A and B domains located in the N-terminal region of each subunit, whereas DNA binding occurs through the bHLH domains. The specific DNA sequences that are targeted by HIF, known as hypoxia-response elements (HREs), are composed of 5′-RCGTG-3′ (where R is either an A or G) and are mostly found in the promoter, intron and/or enhancer regions of target genes (Pugh et al., 1991; Semenza et al., 1991; Wenger et al., 2005).The transcriptional activity of the heterodimer is controlled by transcriptional-activation domains (TADs) found in the C-terminus; HIF1α and HIF2α subunits each have two TADs, known as the N-TAD and C-TAD. The activity of the C-TAD can be inhibited by FIH hydroxylation, but the activity of the N-TAD is independent of FIH. Thus, HIFα has bifunctional transcriptional activity, which, depending
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
RetractedThe biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“VBC covalently links a chain of ubiquitin (Ub) moities to HIFα and causes it to dock onto the multisubunit proteolytic proteasomal complex, which selectively degrades ubiquitin-conjugated proteins (Kaelin and Ratcliffe, 2008).”
BackgroundOxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 2×
“…inactivation of HIFα through posttranslational modification The activities of three well-described HIFα isoforms (HIF1α, HIF2α and HIF3α) are regulated in a similar manner by posttranslational prolyl hydroxylation of the oxygen-dependent degradation domain (ODDD) (Schofield and Ratcliffe, 2004).”
BackgroundHypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
Self-citationNF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α
Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., Johnson, R. S., Haddad, G. G., & Karin, M. (2008) · Nature · doi:10.1038/nature06905 · Cited by 1,614
Bellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouysségur, J., & Mazure, N. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00166-09 · Cited by 1,501
Self-citationTranscriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765
Self-citationRegulation of hypoxia-inducible factor-1α by NF-κB
van Uden, P., Kenneth, N. S., & Rocha, S. (2008) · Biochemical Journal · doi:10.1042/bj20080476 · Cited by 729
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705
Koivunen, P., Hirsilä, M., Günzler, V., Kivirikko, K. I., & Myllyharju, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312254200 · Cited by 447
Dayan, F., Roux, D., Brahimi-Horn, M. C., Pouyssegur, J., & Mazure, N. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4564 · Cited by 294
Self-citationTargeting hypoxia cell signaling for cancer therapy
Melillo, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9059-x · Cited by 230
Cited by
The Pancreas Cancer Microenvironment
Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3114 · Cited by 1,316
Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment
Renner, K., Singer, K., Koehl, G. E., Geissler, E. K., Peter, K., Siska, P. J., & Kreutz, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00248 · Cited by 374
pH control mechanisms of tumor survival and growth
Parks, S. K., Chiche, J., & Pouyssegur, J. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22400 · Cited by 357
Self-citationMethods to study the tumor microenvironment under controlled oxygen conditions
Byrne, M. B., Leslie, M. T., Gaskins, H. R., & Kenis, P. J. A. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.09.006 · Cited by 104
Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part II
Wilczynski, J., Duechler, M., & Czyz, M. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0132-3 · Cited by 41
Metadata
- Authors
- Brahimi-Horn, M. C., & Pouysségur, J.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2009-04-15
- Volume
- 122
- Issue
- 8
- Pages
- 1055-1057
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W2153636620
- Cited by
- 226
- References
- 16
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.